Does the media refer more to DFTX or HIMS?

In the previous week, Definium Therapeutics had 18 more articles in the media than Hims & Hers Health. MarketBeat recorded 36 mentions for Definium Therapeutics and 18 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.80 beat Definium Therapeutics' score of 0.37 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral Hims & Hers Health 8 Very Positive mention(s) 6 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PACS or DFTX?

In the previous week, Definium Therapeutics had 28 more articles in the media than PACS Group. MarketBeat recorded 36 mentions for Definium Therapeutics and 8 mentions for PACS Group. PACS Group's average media sentiment score of 0.44 beat Definium Therapeutics' score of 0.37 indicating that PACS Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral

Does the media refer more to CAI or DFTX?

In the previous week, Definium Therapeutics had 35 more articles in the media than Caris Life Sciences. MarketBeat recorded 36 mentions for Definium Therapeutics and 1 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.95 beat Definium Therapeutics' score of 0.37 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral

Is DFTX or BLLN more profitable?

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -100.30% -69.22% Billiontoone N/A N/A N/A

Does the media prefer DFTX or BLLN?

In the previous week, Definium Therapeutics had 33 more articles in the media than Billiontoone. MarketBeat recorded 36 mentions for Definium Therapeutics and 3 mentions for Billiontoone. Definium Therapeutics' average media sentiment score of 0.37 beat Billiontoone's score of -0.18 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral Billiontoone 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Definium Therapeutics (DFTX) Competitors

$45.35 +3.22 (+7.64%)

As of 11:46 AM Eastern

Compare

DFTX vs. HIMS, PACS, CAI, BLLN, and SHC

Should you buy Definium Therapeutics stock or one of its competitors? MarketBeat compares Definium Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Definium Therapeutics include Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), Billiontoone (BLLN), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does Definium Therapeutics compare to Hims & Hers Health?

Definium Therapeutics (NASDAQ:DFTX) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Definium Therapeutics presently has a consensus price target of $47.08, suggesting a potential upside of 3.81%. Hims & Hers Health has a consensus price target of $29.37, suggesting a potential downside of 5.21%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Definium Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

In the previous week, Definium Therapeutics had 18 more articles in the media than Hims & Hers Health. MarketBeat recorded 36 mentions for Definium Therapeutics and 18 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.80 beat Definium Therapeutics' score of 0.37 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral
Hims & Hers Health	8 Very Positive mention(s)	6 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has higher revenue and earnings than Definium Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Hims & Hers Health	$2.35B	3.05	$128.37M	-$0.09	N/A

Definium Therapeutics has a net margin of 0.00% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Hims & Hers Health	-0.56%	6.10%	1.52%

Summary

Hims & Hers Health beats Definium Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to PACS Group?

PACS Group (NYSE:PACS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

In the previous week, Definium Therapeutics had 28 more articles in the media than PACS Group. MarketBeat recorded 36 mentions for Definium Therapeutics and 8 mentions for PACS Group. PACS Group's average media sentiment score of 0.44 beat Definium Therapeutics' score of 0.37 indicating that PACS Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral

PACS Group currently has a consensus price target of $48.00, indicating a potential upside of 18.85%. Definium Therapeutics has a consensus price target of $47.08, indicating a potential upside of 3.81%. Given PACS Group's higher probable upside, research analysts plainly believe PACS Group is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

PACS Group has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.21	$191.54M	$1.56	25.89
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

PACS Group has a net margin of 4.49% compared to Definium Therapeutics' net margin of 0.00%. PACS Group's return on equity of 26.47% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Definium Therapeutics	N/A	-100.30%	-69.22%

27.9% of Definium Therapeutics shares are held by institutional investors. 70.1% of PACS Group shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

PACS Group beats Definium Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Caris Life Sciences has a net margin of 3.75% compared to Definium Therapeutics' net margin of 0.00%. Caris Life Sciences' return on equity of 98.28% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Definium Therapeutics	N/A	-100.30%	-69.22%

Caris Life Sciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	6.67	-$68.09M	-$7.61	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

In the previous week, Definium Therapeutics had 35 more articles in the media than Caris Life Sciences. MarketBeat recorded 36 mentions for Definium Therapeutics and 1 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.95 beat Definium Therapeutics' score of 0.37 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral

Caris Life Sciences presently has a consensus target price of $27.56, indicating a potential upside of 43.74%. Definium Therapeutics has a consensus target price of $47.08, indicating a potential upside of 3.81%. Given Caris Life Sciences' higher probable upside, research analysts plainly believe Caris Life Sciences is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

27.9% of Definium Therapeutics shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Caris Life Sciences beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Billiontoone?

Definium Therapeutics (NASDAQ:DFTX) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Definium Therapeutics had 33 more articles in the media than Billiontoone. MarketBeat recorded 36 mentions for Definium Therapeutics and 3 mentions for Billiontoone. Definium Therapeutics' average media sentiment score of 0.37 beat Billiontoone's score of -0.18 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral
Billiontoone	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Billiontoone has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Billiontoone	$305.11M	16.92	$7.45M	$0.55	204.14

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Billiontoone	N/A	N/A	N/A

Definium Therapeutics presently has a consensus price target of $47.08, indicating a potential upside of 3.81%. Billiontoone has a consensus price target of $125.29, indicating a potential upside of 11.59%. Given Billiontoone's higher probable upside, analysts clearly believe Billiontoone is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

27.9% of Definium Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Definium Therapeutics and Billiontoone tied by winning 7 of the 14 factors compared between the two stocks.

How does Definium Therapeutics compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Sotera Health presently has a consensus target price of $20.25, suggesting a potential upside of 17.15%. Definium Therapeutics has a consensus target price of $47.08, suggesting a potential upside of 3.81%. Given Sotera Health's higher possible upside, equities research analysts clearly believe Sotera Health is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Sotera Health has a net margin of 9.91% compared to Definium Therapeutics' net margin of 0.00%. Sotera Health's return on equity of 39.73% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
Definium Therapeutics	N/A	-100.30%	-69.22%

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sotera Health has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.24	$77.94M	$0.41	42.16
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

In the previous week, Definium Therapeutics had 36 more articles in the media than Sotera Health. MarketBeat recorded 36 mentions for Definium Therapeutics and 0 mentions for Sotera Health. Definium Therapeutics' average media sentiment score of 0.37 beat Sotera Health's score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sotera Health	Neutral
Definium Therapeutics	Neutral

Sotera Health has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

Summary

Sotera Health beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFTX vs. The Competition

Export

Metric	Definium Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.52B	$493.35M	$6.69B	$12.21B
Dividend Yield	N/A	3.86%	2.68%	5.89%
P/E Ratio	-18.21	3.17	25.35	24.07
Price / Sales	N/A	6,611.90	582.60	125.42
Price / Cash	N/A	13.13	45.29	53.76
Price / Book	13.50	89.10	10.73	6.38
Net Income	-$183.79M	-$96.07M	$3.56B	$336.99M
7 Day Performance	85.25%	1.91%	1.31%	-0.85%
1 Month Performance	101.56%	1.05%	1.09%	0.73%
1 Year Performance	563.01%	69.46%	31.44%	29.29%

Definium Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFTX Definium Therapeutics	1.6789 of 5 stars	$45.35 +7.6%	$47.08 +3.8%	+490.1%	$4.52B	N/A	N/A	40	Trending News Analyst Forecast Analyst Revision
HIMS Hims & Hers Health	3.1369 of 5 stars	$33.60 -5.3%	$29.37 -12.6%	-24.1%	$8.21B	$2.35B	N/A	2,442	Insider Trade Gap Down
PACS PACS Group	4.0411 of 5 stars	$37.79 +3.3%	$48.00 +27.0%	+205.5%	$5.79B	$5.29B	24.23	47,455	Insider Trade
CAI Caris Life Sciences	4.4871 of 5 stars	$17.31 -6.3%	$27.56 +59.2%	N/A	$5.22B	$348.89M	N/A	1,846
BLLN Billiontoone	3.0035 of 5 stars	$100.72 -4.2%	$125.29 +24.4%	N/A	$4.84B	$305.11M	183.13	620	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definium Therapeutics (DFTX) Competitors

DFTX vs. HIMS, PACS, CAI, BLLN, and SHC

How does Definium Therapeutics compare to Hims & Hers Health?

Summary

How does Definium Therapeutics compare to PACS Group?

Summary

How does Definium Therapeutics compare to Caris Life Sciences?

Summary

How does Definium Therapeutics compare to Billiontoone?

Summary

How does Definium Therapeutics compare to Sotera Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definium Therapeutics (DFTX) Competitors

DFTX vs. HIMS, PACS, CAI, BLLN, and SHC

How does Definium Therapeutics compare to Hims & Hers Health?

Do insiders & institutionals have more ownership in DFTX or HIMS?

Do analysts recommend DFTX or HIMS?

Which has more volatility and risk, DFTX or HIMS?

Does the media refer more to DFTX or HIMS?

Which has preferable earnings & valuation, DFTX or HIMS?

Is DFTX or HIMS more profitable?

Summary

How does Definium Therapeutics compare to PACS Group?

Does the media prefer PACS or DFTX?

Do analysts recommend PACS or DFTX?

Which has preferable earnings & valuation, PACS or DFTX?

Is PACS or DFTX more profitable?

Do insiders and institutionals believe in PACS or DFTX?

Summary

How does Definium Therapeutics compare to Caris Life Sciences?

Is CAI or DFTX more profitable?

Which has preferable valuation and earnings, CAI or DFTX?

Does the media refer more to CAI or DFTX?

Do analysts rate CAI or DFTX?

Do insiders & institutionals believe in CAI or DFTX?

Summary

How does Definium Therapeutics compare to Billiontoone?

Does the media prefer DFTX or BLLN?

Which has higher valuation and earnings, DFTX or BLLN?

Is DFTX or BLLN more profitable?

Do analysts rate DFTX or BLLN?

Do insiders and institutionals hold more shares of DFTX or BLLN?

Summary

How does Definium Therapeutics compare to Sotera Health?

Do analysts prefer SHC or DFTX?

Is SHC or DFTX more profitable?

Do institutionals & insiders hold more shares of SHC or DFTX?

Which has preferable earnings and valuation, SHC or DFTX?

Does the media refer more to SHC or DFTX?

Which has more risk and volatility, SHC or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools